Evidence map›Paper›PMID 35493459›Full record

ArticleFrontiers in immunology2022

CCDC88A Post-Transcriptionally Regulates VEGF

Qiongying Hu, Yuchen Li, Hongqing Chen, Hongyan Liao, Yong He, Qin Zheng

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
4.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Qiongying HuDepartment of Laboratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Yuchen LiDepartment of Laboratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Hongqing ChenDepartment of Laboratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Hongyan LiaoDepartment of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, China.
Yong HeDepartment of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, China.
Qin ZhengDepartment of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, China.
West China Hospital of Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: miR-101 is one of the most abundantly expressed microRNA (miRNA) and exerst a critical role in hepatocellular carcinoma (HCC) by targeting to 3' -untranslated region (UTR) of Girders of actin filaments (CCDC88A) and Vascular endothelial growth factor (VEGF) mRNA, but the underlying molecular mechanism remains to be elucidated. This study aimed to investigate the potential role of CCDC88A on malignancies and stemness by regulating VEGF Methods: Gene Expression Profiling Interactive Analysis (GEPIA) was employed to analyze the relevance of CCDC88A expression with prognosis in HCC. Tissue slides were performed to confirm the protein level of CCDC88A in HCC. Correlation between CCDC88A and VEGF was transcriptionally and post-transcriptionally detected, followed by evaluation of malignancies. Results: By employing Immunohistochemistry, we found CCDC88A protein was upregulated in HCC tissues, which is closely correlated to poor prognosis and survival rate. Employment of GEPIA revealed the positive correlation between CCDC88A and VEGF in HCC, but not in liver tissue. Silencing of CCDC88A in Huh-7 and SK-HEP-1 cells significantly decreased proliferation, cell cycle phases, migration, invasion, colony formation, and tumor formation. Introduction of miR-101 mimics specifically targeting CCDC88A and VEGF decreased protein levels of both CCDC88A and VEGFA. Notably, inhibition of miR-101 reversed the correlation between CCDC88A and VEGFA protein levels, indicating that CCDC88A and VEGF may exert as a miR-101 sponge. The addition of SKLB1002, a VEGFR2 inhibitor inhibited malignant behaviors, which was further inhibited by the introduction of miR-101 mimics, indicating that CCDC88A regulates malignant behaviors partially Conclusion: Taken together, our findings suggested that the miR-101/CCDC88A/VEGF axis could be a potential therapeutic target of HCC treatment.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsMicroRNAs3' Untranslated RegionsGene Expression Regulation, NeoplasticHumansMicrofilament ProteinsVascular Endothelial Growth Factor AVesicular Transport Proteins3' Untranslated RegionsCCDC88A protein, humanMicrofilament ProteinsMicroRNAsMIRN101 microRNA, humanVascular Endothelial Growth Factor AVesicular Transport Proteinscancer stem-like cells (CSCs)Girders of actin filaments (CCDC88A)hepatocellular carcinoma (HCC)malignant behaviormicroRNA-101vascular endothelial growth factor (VEGF)

Identifiers

PMID35493459
PMCPMC9043556
OpenAlexW4224133249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.